NEW YORK and KING OF PRUSSIA, Pa., May 22, 2015 /PRNewswire/ -- The National
Hemophilia Foundation (NHF) has awarded CSL Behring its 2015
Corporate Leadership Award as recognition for the company's
longstanding and unwavering commitment to advancing science and
improving the care of the bleeding disorders community. The
award was accepted by Paul
Perreault, CEO and Managing Director, CSL Limited, during
the NHF Annual Spring Soiree in New York
City on May 21.
"The National Hemophilia Foundation is dedicated to finding
better treatments and cures for bleeding disorders," said
Val Bias, Chief Executive Officer of
NHF. "CSL Behring shares NHF's vision and commitment to providing
education, advocacy and research opportunities that strive to
improve the well-being of patients and their caregivers. We
applaud CSL Behring's leadership and dedication to delivering
innovative products and programs that make a meaningful difference
in the lives of the bleeding disorders community."
World-class research and development, high quality
manufacturing, and patient-centered management are the longstanding
hallmarks of CSL Behring in serving the bleeding disorders
community. Driven by its commitments to the community, CSL Behring
develops and delivers innovative protein-based therapies, and
leading educational and emotional support programs that improve the
lives of people living with hemophilia, von Willebrand disease and
other serious bleeding disorders. By closely partnering with the
hemophilia community, CSL Behring has achieved significant
advancements in its Recombinant Factor Development program which,
upon regulatory approvals, will provide hemophilia A and B patients
with new treatment options.
The company also continues to advance patient, caregiver and
researcher support through highly impactful programs,
including:
- My Source℠ program -- one-stop location for CSL Behring's
patient-support resources for the U.S. bleeding disorders
community
- Common Factors series of educational events
- My Access℠ cost share program
- Gettin' in the Game℠ events and the Gettin' in the Game℠ Junior
National Championship program
- CSL Behring Professor Heimburger Award for Coagulation
Research
- Pledge to the World Federation of Hemophilia to donate bleeding
disorder therapies and provide financial contributions.
To learn about CSL Behring's programs for the U.S. bleeding
disorders community, please visit: www.MySourceCSL.com.
"CSL Behring has long been at the forefront of protecting the
health of people living with a range of serious and chronic medical
conditions," said Paul Perreault,
CEO and Managing Director of CSL Limited. "NHF's goals align with
our focus to develop and deliver innovative products and programs
that save people's lives and improve the quality of their lives. On
behalf of CSL's 14,000 employees around the world who are driven by
our deep passion and commitment to the global bleeding disorders
community, I'd like to thank NHF for recognizing us with this
year's Corporate Leadership Award."
About the Spring Soiree
The Annual Spring Soiree publically acknowledges outstanding
leaders whose exemplary contributions have significantly advanced
NHF's mission to find better treatment and cures for bleeding
disorders and to prevent the complications of these disorders.
About NHF
The National Hemophilia Foundation (NHF) is
dedicated to finding better treatments and cures for inheritable
bleeding disorders and to preventing the complications of these
disorders through education, advocacy and research. There are over
400,000 people worldwide who are affected by hemophilia, an
inheritable bleeding disorder in which the blood does not clot
normally. Seventy percent of these individuals do not have access
to treatment and care, resulting in severe joint damage, extreme
pain, and possible life-threatening bleeds. NHF is the premier
organization in the U.S. serving the bleeding disorders community.
For more than 65 years, NHF continues to be a vital resource for
prevention education and provides a network of support for the
estimated 20,000 Americans living with hemophilia and their
families.
About CSL Behring
CSL Behring is a leader in the
plasma protein therapeutics industry. Committed to saving lives and
improving the quality of life for people with rare and serious
diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat
coagulation disorders including hemophilia and von Willebrand
disease, primary immune deficiencies, hereditary angioedema and
inherited respiratory disease, and neurological disorders in
certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent
hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma
collection networks, CSL Plasma. CSL Behring is a global
biopharmaceutical company and a member of the CSL Group of
companies. The parent company, CSL Limited (ASX:CSL), is
headquartered in Melbourne,
Australia. For more information, visit
www.cslbehring.com.
Contact:
John Indence
National Hemophilia Foundation
Office: 212-328-3763
Jinden@hemophilia.org
Greg Healy
CSL Behring
Office: 610-878-4841
Mobile: 610-906-4564
Greg.Healy@CSLBehring.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/national-hemophilia-foundation-honors-csl-behring-with-corporate-leadership-award-300087820.html
SOURCE CSL Behring